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Abstract. The interaction between zaleplon (ZAL) and different cyclodextrins in aqueous solutions was 
investigated by spectrofluorimetric and phase solubility studies. Stability constants determined by both 
methods showed that among natural cyclodextrins, β-cyclodextrin (βCD) formed the most stabile complex 
but its solubilizing efficiency was limited. Among βCD derivatives, the complex stability and solubilisa-
tion efficiency decreased in order: randomly methylated-βCD (RAMEB) > sulphobutylether-βCD 
(SBEβCD ) > hydroxypropyl-βCD (HPβCD). The inclusion complexes of ZAL with βCD and RAMEB 
were further characterised by 1H-NMR spectroscopy and the inclusion complex formation was confirmed 
in both cases. ROESY spectra showed two binding modes between ZAL and βCD which exist simulta-
neously in the solution. The first binding mode occurs by the inclusion of the phenyl ring of ZAL into the 
βCD central cavity via the wider rim of the cyclodextrin cone and is dominant. The second one is formed 
by the inclusion of pyrazolo[1,5-a]pyrimidine ring of ZAL.(doi: 10.5562/cca1800) 




midin-7-yl)phenyl]-N-ethylacetamide, is a nonbenzo-
diazepine hypnotic drug of the pyrazolopyrimidine 
class. In the dose of 5 to 10 mg, the drug is indicated for 
the short term management of insomnia.1,2 ZAL also 
shows potent anticonvulsant activity against electro-
shock-induced convulsions.3 The drug is a lipophilic 
compound which is virtually insoluble in water.4 It has 
been recognised that a certain level of aqueous solubili-
ty is required of the drug substance to be readily deli-
vered to the cellular membrane, but at the same time it 
has to be lipophilic enough to cross the membrane itself. 
In the case of lipophilic compounds such as ZAL, the 
dissolution in gastrointestinal media is often a rate-
limiting step for the absorption, thus limiting the oral 
bioavailability of the drug.5 In the liver, ZAL is exten-
sively metabolized into pharmacologically inactive 
metabolites.3 Low aqueous solubility of ZAL and its 
significant presystemic metabolism lead to a rather low 
oral bioavailability of about 30 %.6 
Various formulation techniques can be applied to 
overcome the low aqueous solubility of drugs without 
affecting their optimised pharmacological action. Among 
different approaches for enhancing the aqueous solubility 
of lipophilic drugs, cyclodextrin (CD) complexation 
proved to be one of the most effective.7 Cyclodextrins are 
a group of structurally related oligosaccharides, consisting 
of 6, 7 or 8 (α-1,4)-linked α-D-glucopiranose units (α-, β- 
and γ-CD, respectively), derived from bacterial starch 
degradation. The shape of cyclodextrins is a truncated 
cone with a central cavity, due to the chair conformation 
of the glucopiranose units. The hydroxyl groups of gluco-
piranose units are oriented to the exterior of the molecule, 
giving it hydrophilic character. The central cavity of cyc-
lodextrin is lined by skeletal carbons and ethereal oxygens 
of the glucose residues, which gives it a relatively lipo-
philic character. As a consequence of such structure, cyc-
lodextrins are able to form inclusion complexes by encap-
sulating either partially or entirely a great number of mo-
lecules of suitable size into their central cavities. No cova-
lent bonds are formed or broken during the inclusion 
complex formation and a fast equilibrium between the free 
and the complexed drug exists in an aqueous solution. The 
inclusion complex formation may favourably modify 
undesired biopharmaceutical properties of the drug, such 
as low chemical stability and limited aqueous solubility, 
leading to improved drug bioavailability.8−10 
Cyclodextrins are biocompatible molecules with 
limited absorption in the gastrointestinal tract. Due to 
their high molecular weight and hydrophilic character, 
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cyclodextrins can permeate the gastrointestinal mucosa 
only with considerable difficulty. Therefore, cyclodex-
trins act as carriers of lipophilic drug molecules in the 
hydrophilic gastrointestinal media, delivering the drug to 
the surface of the gastrointestinal mucosa, where the 
complex dissociation and absorption of the free drug 
occur.9,11 Additionally, free cyclodextrins can interact 
with gastrointestinal mucosa, reversibly increasing its 
permeability for the drug, thus acting as permeation en-
hancers.7 The bulk of orally administered cyclodextrins is 
metabolised by the microflora present in the colon. The 
primary metabolites formed, such as maltodextrins, mal-
tose and glucose are then absorbed into systemic circula-
tion and finally metabolised to CO2 and H2O.
7 
Among natural derivatives, βCD is the most com-
monly used in pharmaceutical formulations due to a 
cavity size suitable for a wide range of drugs.8,9 Howev-
er, due to the relatively strong hydrogen binding in the 
crystal lattice, the aqueous solubility of βCD is much 
lower compared to the corresponding acyclic dextrins. 
The interaction of βCD with lipophilic drugs may result 
in the inclusion complexes of limited aqueous solubility 
as well. Therefore, a series of chemically modified βCD 
derivatives have been synthesized in order to extend the 
physicochemical properties and the inclusion capacity 
of the parent βCD.9 Several amorphous βCD derivatives 
with improved aqueous solubilities have been devel-
oped, and some among them are proved to be safe even 
for parenteral application, such as hydroxypropyl-, sul-
phobutylether- or malthosyl-β-cyclodextrin.7,11 
The inclusion complex formation of ZAL with par-
ent βCD has already been reported, resulting in the signif-
icant improvement of its aqueous solubility.12 The effec-
tiveness of cyclodextrins as drug carriers can be signifi-
cantly influenced by the size of the cavity and the type of 
substituents present on the cyclodextrin core. In many 
cases, hydrophilic derivatives of βCD have exhibited 
superior ability to solubilize and form complexes with 
different drugs compared to the parent βCD.13−15 There-
fore, it seemed of interest to extend the range of the in-
vestigated CDs to a series of native and modified cyclo-
dextrins, in order to select the carriers with the greatest 
solubilizing and complexing efficacies towards ZAL. The 
interaction of ZAL with selected cyclodextrins in an 
aqueous solution was investigated by spectrofluorimetry 
and phase solubility studies, while 1H-NMR spectroscopy 
was used to confirm the actual inclusion complex forma-




All water used was deionized and then twice distilled in 
an all-glass apparatus, first from an alkaline solution of 
KMnO4. Zaleplon (99.7 % purity) was kindly donated 
by Belupo d. d. (Croatia). The cyclodextrins included in 
this study were natural, α-, β-, γ-cyclodextrin (αCD, 
βCD and γCD, respectively) and β-cyclodextrin deriva-
tives; hydroxypropyl-β-cyclodextrin (HPβCD) and 
randomly methylated-β-cyclodextrin (RAMEB), which 
were all obtained from Wacker Chemie GMBH (Ger-
many). Average degrees of substitution per anhydroglu-
cose unit are 0.9 and 1.8 for HPβCD and RAMEB, 
respectively. Sulphobutylether-β-cyclodextrin sodium 
salt with a substitution degree of 0.9 (SBE-β-CD) was 
obtained from CyDex Inc (USA). D2O (Sigma), MeOH 
(Sigma) and all other chemicals and solvents used in 
this study were of analytical reagent grade. 
 
Fluorescence studies 
Zaleplon stock solution was prepared by dissolving an 
appropriate amount of drug in a small amount of MeOH 
and then diluted with water to the final concentration of 
0.1 mM. The final amount of MeOH in the stock solu-
tion was 1 % v/v. For each experiment, 3 mL of ZAL/CD 
solutions of appropriate concentration were prepared and 
left for an hour to equilibrate. The final concentration of 
zaleplon was 10 μM and the cyclodextrin concentration 
varied from 0.1 mM to 40 mM, depending on the cyclo-
dextrin solubility. MeOH was 0.1 % v/v in the final solu-
tions. Fluorescence was measured by OLIS RSM 1000F 
spectrofluorimeter (Bogart, Georgia, USA) equipped 
with thermostatted cell at 25 °C. The excitation wave-
length was 393 nm and the emission spectrum of pure 
zaleplon exhibited a maximum at 487 nm. Each spec-
trum presented in titration curves is an average of 10 000 
fluorescence spectra measured in 10 seconds. Equili-
brium constants were calculated by a global fit at all 
wavelengths performed with Specfit® software. 
 
Phase solubility studies 
Phase solubility studies of ZAL with different cyclodex-
trins were performed according to the method described 
by Higuchi and Connors.16 An excess amount of the 
drug (50 mg) was added to 20 ml of an aqueous cyclo-
dextrin solution and stirred at a constant temperature 
(25.00.5 oC) in sealed containers for 72 hours until 
complexation equilibrium was reached. The concentra-
tions of the cyclodextrins ranged from 0 to 48 mM, 
except for βCD, whose concentration ranged from 0 to 
12.5 mM due to its limited aqueous solubility. After the 
complexation equilibrium was reached, aliquots of the 
samples were filtered through 0.45 m Millipore mem-
brane filter and the drug concentrations in the filtrate 
were determined spectrophotometrically at 335 nm 
(Ultrospec Plus, LKB, Pharmacia, Sweden). Preliminary 
studies showed that the presence of cyclodextrins did 
not interfere with ZAL absorbance at 335 nm. 
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1H-NMR studies 
All NMR spectra were recorded at 300 K on a Bruker 
DRX 400 spectrometer (Karlsruhe, Germany) by using 
an inverse multinuclear (bbi) single-axis gradient 5 mm 
probe. The samples were prepared by dissolving ap-
proximately 0.5 mg of the drug and 5 mg of the cyclo-
dextrin or an equimolar drug/cyclodextrin complex in 
0.5 ml D2O. The signal of residual water at 4.80 ppm 
was used as an internal reference to avoid interferences. 
Two-dimensional diffusion ordered NMR spectroscopy 
(DOSY) was performed using the longitudinal eddy 
current delay experiment with bipolar gradients 
(ledbpgp2s standard program from Bruker pulse se-
quence library). The gradient intensity was varied li-
nearly in 64 steps from 2 to 95 % of the maximum gra-
dient strength (50 G cm−1). The gradient pulse duration 
and diffusion delay were set at 4 ms and 50 ms, respec-
tively. 16 K data points were acquired in f2, and 64 
scans were collected for each gradient increment. The 
diffusion constants were determined by fitting an expo-
nential decay function to the obtained peak intensities 
using the relaxation analysis module of Bruker TopSpin 
2.5 program. Two-dimensional ROESY experiments 
were performed using the standard Bruker pulse pro-
gram (roesytp) with a relaxation delay of 1.7 s and a 
mixing time of 300 ms under cw spinlock conditions. 
ROESY spectra were recorded with 2048 data points in 
f2, 400 data points in f1, and 64 scans were collected at 
each increment. 
 
RESULTS AND DISCUSSION 
In this paper we studied the interaction of natural and 
modified cyclodextrins with zaleplon in order to under-
stand the behaviour of these complexes in an aqueous 
solution and to evaluate their potential for eventual use 
in medicine (Scheme 1). 
Stability constants and the modalities of binding 
were our primal goals in this study. Zaleplon exhibits 
emission spectra in the visible region when excited at 
393 nm. This characteristic was used in study of the 
reactions with cyclodextrins which show no fluores-
cence in that region. Titration curves were measured 
with all cyclodextrins in order to establish the stoichi-
ometry of the complex and the values of the stability 
constants. Figure 1 shows fluorescence spectra of zalep-
lon and its complexes with the investigated cyclodex-
trins. In all cases the intensity and the spectral maxima 
of the zaleplon emission spectra were changed upon 
addition of the CD, indicating a change of polarity in 
the close proximity of the zaleplon molecule. 
When a guest molecule is entrapped in the CD 
cavity, this microenvironment with a smaller polarity 
and a stronger rigidity would restrict the freedom of the 
guest molecule and consequently increase the fluores-
cence quantum yield.17,18 In addition, the steric hin-
drance of CD can protect the excited states from 
quenching processes and enhance the fluorescence effi-
ciency. Titration curves were measured with all investi-
gated cyclodextrins and a typical titration of ZAL with 
βCD is shown in Figure 2. In all titrations an increase of 
quantum yield was observed during the titration (Fig-
ures S1−S5, supplemental). 
All spectra in the titrations were analysed with 
Specfit19−21 software and only two spectrally active 
species were suggested by SVD (single value decompo-
sition) statistical analysis, one attributed to zaleplon and 
the other one to its complex with cyclodextrin. This 
analysis suggested only 1 to 1 complex formation and 
did not indicate higher order complexes in all cases. 




ZAL  CD ZAL CD,     
ZAL CD  
K
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    (1) 
The stability constants KFL for given model are summa-
rized in Table 1. Scheme 1. Reaction of Zaleplon with Cyclodextrins 
Figure 1. Spectral species obtained by spectrofluorimetric 
titrations of Zaleplon with natural and modified cyclodextrins. 
Molar fluorescence coefficients, η, are given in 105 fluores-
cence units per mol dm-3. Inset: Calculated spectral maxima of 
complexes. 
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Stability constants obtained by spectrofluorimetric 
studies indicated that the ZAL/βCD complex has the 
highest stability of natural CDs, indicating the most 
appropriate size for fitting ZAL into its central cavity. 
The presence of the substituents on βCD (RAMEB, 
SBEβCD and HPβCD) probably sterically hinders the 
inclusion of the drug and consequently decreases the 
stability constants. 
The solubilizing effect of each cyclodextrin deriv-
ative on the drug was investigated by phase solubility 
studies. In case of all cyclodextrins, ZAL solubility 
increased linearly (r2 > 0.98) as a function of CD con-
centration (Figure 3), showing an AL type of diagram, 
according to Higuchi and Connors.16 
This suggested the formation of soluble inclusion 
complexes with 1:1 drug/cyclodextrin molar ratio, irres-
pective of the type of cyclodextrin used. This is in 
agreement with the results of spectrofluorimetric stu-
dies, which also indicated the same complex stoichi-
ometry. The apparent stability constant of the inclusion 
complexes formed (KSOL) was calculated according to 










where tgα represents the slope of the phase solubility 
diagram and s0 is the solubility of zaleplon in the absence 
of cyclodextrin. The obtained values of KSOL are also pre-
sented in Table 1. The slight discrepancy between Ks val-
ues obtained by spectrofluorimetric and phase solubility 
studies may be related to differences in experimental 
Figure 2. A typical titration of 10 μM solution of ZAL with
βCD at 25°C, l = 1 cm. The concentration of βCD was varied
up to 9 mM. Fluorescence units (f.u.) are given as a ratio of
signals obtained from sample and reference PMTs. Inset:
Fitting curve at 482 nm. 
Table 1. Stability constants of ZAL/CD complexes measured by fluorescence (KFL) and solubility (KSOL) studies and solubiliza-
tion efficiency 
    CD KFL / (mol
−1 dm3) KSOL(mol
−1 dm3) Solubilization efficiency(a) 
αCD 141.25 ± 1.70   20.81 ± 2.37 1.99 
βCD 331.13 ± 1.17 112.85 ± 0.23 2.24 
HPβCD   16.98 ± 1.23   53.58 ± 3.59 3.48 
RAMEB 107.15 ± 1.28 156.21 ± 4.61 7.83 
SBEβCD   67.61 ± 1.07   84.83 ± 0.44 4.80 
γCD     9.33 ± 1.34   41.10 ± 3.03 2.85 
Figure 3. Phase solubility studies of ZAL with natural (α-, β-
and γ-CD) and β-CD derivatives (HPβCD, RAMEB and
SBEβCD) in water at 25°C (mean±SD). 
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techniques, particularly in the drug concentration and 
presence of co-solvents. In the spectrofluorimetric study, 
the drug concentration was kept constant and a small a-
mount (0.1 % v/v) of methanol as co-solvent was used. On 
the contrary, the phase solubility studies were performed 
in pure aqueous solutions of the cyclodextrin where the 
drug concentration varied as a function of cyclodextrin 
amount in the sample. Furthermore, the stability constant 
determined from the phase solubility studies frequently 
corresponds to several different solubilisation phenomena, 
such as inclusion and non-inclusion complex formation, 
aggregation etc. that exist simultaneously in non-ideal 
aqueous solutions of cyclodextrins. All this may contri-
bute to differences of stability constants measured by both 
methods, as previously reported by Loftsson et al.22 
Both spectrofluorimetric and phase solubility stu-
dies showed that among natural cyclodextrins, βCD 
formed the most stabile inclusion complexes with ZAL, 
while the stability of ZAL complexes with αCD and γCD 
was significantly lower. This can probably be attributed 
to the differences of central cavity sizes between natural 
CDs. The central cavity of αCD is probably too small to 
suitably fit the guest, resulting in a lower complexing 
affinity towards ZAL than in the case of βCD. On the 
other hand, the excessively large cavity of γCD did not 
allow sufficiently strong interaction between the host and 
the guest molecule. Similar findings were also observed 
by other authors.23,24 
To estimate the solubilizing efficiency of each cyc-
lodextrin, the ratio between ZAL solubility in the most 
concentrated cyclodextrin solution and in pure water was 
calculated (Table 1). The solubilizing efficiency of natural 
CDs followed the trend γCD > βCD > αCD. Although 
βCD formed the most stabile complexes, its solubilizing 
efficiency was somewhat reduced due to its limited 
aqueous solubility.25 All βCD derivatives showed superior 
solubilizing efficiency compared to the parent βCD (Table 
1) and RAMEB was found to be the most effective com-
plexing agent for ZAL. The substitution of the hydroxyl 
group at the βCD core with methyl groups resulted in the 
remarkable increase of the aqueous solubility of the 
formed carrier.11 This probably led to a higher solubilisa-
tion efficiency of RAMEB for ZAL, compared to the 
parent βCD. The surface activity of the methylated cyclo-
dextrins probably additionally contributed to the overall 
solubilizing effect.26 Furthermore, the presence of the 
rather lipophilic methoxy groups at the βCD core might 
allow a stronger interaction with the lipophilic guest mole-
cule, stabilizing its inclusion into the host cavity (Table 1). 
In the case of other βCD derivatives, a decrease of 
solubilizing efficiency and complex stability was ob-
served. The introduction of more bulky substituents on 
the βCD core, such as the hydroxypropylated and sul-
phobutylated groups, lowered the complexation affinity 
of such derivatives for ZAL by providing a hydrogen 
bonding source for the water molecules, which in turn 
decreased the energy difference between the water mo-
lecules included into the CD central cavity and those in 
the bulk of the solution. Furthermore, the presence of 
bulky, highly hydrated or highly charged groups near 
the βCD cavity may inhibit the approach of a hydro-
phobic molecule,9 thus decreasing the affinity of such 
derivatives for complexation with ZAL (Table 1). 
The increased aqueous solubility of the drug and 
enhancement of its fluorescence in the presence of cyc-
lodextrins observed by the phase solubility studies and 
spectrofluorimetry cannot be taken as an ultimate proof 
of the actual formation of an inclusion complex. These 
techniques cannot provide a clear answer about the 
drug/cyclodextrin interaction mode (inclusion or ad-
sorption), or provide an insight into the structure of the 
formed complexes.27 Therefore, the interaction between 
ZAL and βCD or RAMEB was further characterised by 
1H-NMR studies. The assignment of 1H chemical shifts 
of ZAL, βCD and RAMEB was done according to the 
related literature27−29 and corroborated by COSY spec-
troscopy (data not shown). The proton labels of ZAL 
and the studied cyclodextrins are presented in Figure 4. 
Figure 4. Structures and proton labelling of zaleplon (1) and the cyclodextrins used in the study (2). 
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In 1H-NMR spectra of all studied binary systems, 
the drug signals were well separated from those of cyc-
lodextrins, with the exception of the Hb signal of ZAL, 
which was overlapped by the signals of cyclodextrin 
protons. No new peaks were observed in 1H-NMR spec-
tra of ZAL/CDs samples, indicating that the guest mole-
cule was in a rapid exchange between free and complex 
form, relative to the NMR timescale.30 βCD exhibited a 
well resolved 1H-NMR spectrum and its assignments 
are presented in Table 2. 
The H3 and H5 protons, which are lining the interior 
of the cyclodextrin central cavity, as well as the H6 pro-
ton, which is located at the narrower end of the cyclodex-
trin torus, experienced a shielding effect resulting in their 
up-field shift (Δδ < 0). Other βCD protons, namely H1, 
H2 and H4, which are located on the exterior of the cyclo-
dextrin molecule showed only a minor change of their 
resonance. This may be taken as a clear suggestion of an 
inclusion complex formation between ZAL and βCD. In 
particular, the observed shielding effect can be attributed 
to the diamagnetic anisotropy effect due to the inclusion of 
a group rich in π-electrons into the hydrophobic central 
cavity of the cyclodextrin molecule.31 Furthermore, the 
fact that the shielding effect was observed for H3, H5 and 
H6 indicated that the ZAL molecule penetrated deeply 
into the cyclodextrin central cavity. The higher shielding 
effect on the H3 proton with respect to those of H5 and H6 
(ΔδH3 > ΔδH5 ≥ ΔδH6), shows that the inclusion of ZAL 
into βCD cavity probably occurred via a more accessible 
wider side of the cyclodextrin molecule (i.e. the secondary 
hydroxyl rim of the torus)13,27 
Further information about ZAL/βCD inclusion 
complex formation was obtained by analysing the 
chemical shift values of the drug molecule (Table 3). 
Table 2. 1H-NMR chemical shifts of β-CD and RAMEB in free and complex form, determined in D2O at 300 K. The multiplici-
ties of peaks are indicated in brackets (s-singlet; d-doublet; dd-doublet of doublets; t-triplet) 
proton 
label 
βCD βCD complex RAMEB RAMEB complex 
δ / ppm δ / ppm Δδ(a) / ppm δ / ppm δ / ppm Δδ(a) / ppm 
H1  5.165 (d)  5.159 (d) −0.006 5.366 (d) 5.360 (d) −0.006 
H2     3.757 (dd)     3.753 (dd) −0.004 - - - 
H3 4.055 (t) 4.027 (t) −0.028 - - - 
H4 3.674 (t) 3.668 (t) −0.005 - - - 
H5 3.943 (s) 3.927 (s) −0.017 - - - 
H6 3.968 (s) 3.956 (s) −0.012 - - - 
Me 2' - - - 3.662 (s) 3.662 (s) 0.000 
Me 6' - - - 3.490 (s) 3.485 (s) −0.005 
(a) Δδ = δcomplex − δfree 
Table 3. 1H-NMR chemical shifts of ZAL in free and complex form with β-CD and RAMEB determined in D2O at 300 K. The 
multiplicities of peaks are indicated in brackets (s-singlet; d-doublet; t-triplet; q-quartet) 
ZAL βCD complex RAMEB complex 
proton label δ / ppm δ / ppm Δδ(a) / ppm δ / ppm Δδ(a) / ppm 
Ha 1.224 (t) 1.294 (t) 0.069 1.293 (t) 0.069 
Hb 3.859 (q) -(b) -(b) -(b) -(b) 
Hc 2.012 (s) 2.063 (s) 0.051 2.043 (s) 0.031 
Hd 8.089 (d) 8.221 (d) 0.132 8.264 (d) 0.175 
He 7.856 (t) 7.979 (t) 0.123 7.990 (t) 0.134 
Hf 7.544 (d) 7.651 (d) 0.108 7.650 (d) 0.106 
Hg 8.028 (s) 8.067 (s) 0.039 8.094 (s) 0.066 
Hh 7.728 (d) 7.670 (d) −0.058 7.716 (d) −0.012 
Hi 8.945 (d) 8.965 (d) 0.020 9.063 (d) 0.118 
Hj 8.690 (s) 8.722 (s) 0.033 8.701 (s) 0.011 
(a) Δδ = δcomplex − δfree. 
(b) overlapped by cyclodextrin signal. 
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The majority of the drug protons showed a down-field 
shift in the presence of βCD (Δδ > 0), while only Hh 
proton was shifted up-field. A down-field shift may be 
related to changes in the local polarity due to the inclu-
sion of the drug into the lipophilic central cavity of the 
cyclodextrin molecule or to the deshielding effects 
caused by the van der Waals interaction between the 
drug and the carbohydrate chains.31 The most affected 
ZAL protons were Hd, He and Hf, indicating that the 
interaction of the phenyl ring of the drug molecule with 
the central cavity of βCD was the most intense one. 
Furthermore, the Ha and Hc protons experienced a 
somewhat stronger shielding effect compared to Hi and 
Hj, which may indicate that Ha and Hc are located more 
deeply into lipophilic central cavity of βCD. Up-field 
shift of Hh proton indicated that this proton is close to a 
host atom rich with π-electrons, which in this case is 
associated with the oxygen atom of βCD, but also re-
flected some conformational changes produced by the 
inclusion.32 Based on these results, it may be assumed 
that the whole drug molecule is included into the central 
cavity of the βCD. 
1H-NMR spectrum of RAMEB was not well re-
solved because it is not a single pure compound, but 
rather a complex mixture of randomly methylated mole-
cules of βCD.29 As a result, only some of the RAMEB 
signals could be unambiguously identified (Table 2). 
While comparing the chemical shifts of H1, Me2 and 
Me6 of RAMEB in free and complex form (Table 2), it 
may be seen that these protons experienced only minor 
shielding effect or none at all. Signals of other RAMEB 
protons are uncertain and cannot be used for interpreta-
tion of the drug inclusion mode. Therefore, information 
about the inclusion complex formation between ZAL 
and RAMEB was deduced solely on the basis of chemi-
cal shift changes of the drug (Table 3). Similarly as in 
the case of βCD, Hd, He and Hf were the most influ-
enced protons of the drug, indicating a similar 
guest/host binding mode as well. Interestingly, the 
chemical shift change of those protons was more pro-
nounced with RAMEB than in the case of βCD. This 
increasing chemical shift perturbation can be attributed 
to a higher fraction of bound drug molecules, which is 
consistent with the stability constant values obtained by 
phase solubility studies. We have previously observed 
similar behaviour in the case of the inclusion complexes 
between bupivacaine hydrochloride and several βCD 
derivatives.33 Furthermore, the more pronounced down-
field shift of Hi proton and the reduced up-field shift of 
Hh proton observed for RAMEB complex (Table 3) 
may be attributed to a changed microenvironment due to 
the presence of the methyl groups on the βCD core. 
Further evidence for the inclusion complex forma-
tion between ZAL and the selected cyclodextrin deriva-
tives was obtained by DOSY spectroscopy. The average 
diffusion coefficient of the drug was determined analys-
ing the DOSY signals of Ha, Hc, Hf, Hd, Hi and Hj 
protons. For βCD, the average diffusion coefficient was 
determined analysing the DOSY signals of H1, H2, H3, 
H4 and H6, while in case of RAMEB, H1, Me2 and 
Me6 DOSY signals were taken into calculation. A pair 
of values was obtained for both cyclodextrin complexes, 
because the average diffusion coefficients were calcu-
lated by taking into account the DOSY signals of the 
drug and the signals of the corresponding cyclodextrin. 
The obtained results are presented in Table 4. 
In the presence of both cyclodextrins (Table 4), 
ZAL showed a significant reduction of the diffusion 
rate, compared to that of the pure drug. Since the viscos-
ity change is negligible in the diluted cyclodextrin solu-
tion compared to pure water, this change confirmed the 
formation of a relatively stable inclusion complexes of 
ZAL with both cyclodextrins studied. The extent of the 
reduction of the diffusion coefficient is well correlated 
with the molecular weight of cyclodextrins. In the case 
of βCD (MW 1135 g mol−1), the drug diffusion rate was 
reduced approximately 32 %, while in the case of RA-
MEB (MW 1303 g mol−1) the reduction was about 50 
%, both compared to the diffusion coefficient of the 
pure drug. This is in agreement with the molecular 
weight differences of complexes formed. For both com-
plexes the diffusion coefficients calculated from DOSY 
signals of ZAL and CDs are slightly different. In the 
presence of both cyclodextrins, the diffusion of the drug 
was significantly reduced with respect to that of the free 
drug, although it is not completely the same as that 
calculated on the basis of DOSY signals of the CDs 
(Table 4). This may be related to the fast equilibrium 
between the bonded and the free drug, as suggested by 
Pescitelli et al.34 Assuming that the bound and the free 
ZAL undergo a fast exchange on the diffusion time-
scale, the observed ZAL diffusion coefficient (Dobs) is 
an average of the bound (Dcomplex) and the free (Dfree) 
drug: 
obs free free complex complexD f D f D     (3) 
Table 4. The average diffusion coefficients of drug and both 
cyclodextrins in free or in the complex form. The values in 
brackets represent the standard deviation 
  
D × 1010/(m2 s−1) 
ZALaverage CDaverage 
ZAL 5.196 (0.013) - 
βCD - 3.103 (0.014) 
βCD-complex 3.526 (0.041) 3.107 (0.014) 
RAMEB - 2.428 (0.080) 
RAMEB-complex 2.460 (0.008) 2.380 (0.001) 
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where ffree and fcomplex are the fractions of the free ZAL 
and the drug bonded to cyclodextrin complex. The frac-
tion of the drug in complex may be expressed as: 
complexed free1f f   (4) 













Recognising that molecular weight of ZAL (305.34 
g mol−1) is much smaller than that of cyclodextrins, it can 
be assumed that the diffusion coefficient of the host is not 
greatly perturbed by the binding of a small guest mole-
cule. Therefore, the diffusion coefficient of the host-guest 
complex can be assumed to be the same as that of the 
non-complexed host molecule alone.35−37 Consequently, 













Figure 5. Partial contour plots of 2D ROESY spectrum of ZAL in the presence of βCD (A, B) and RAMEB (C, D) in D2O at
300 K. For the proton labelling see Figure 4. 
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Using the Eq. (6), the fraction of ZAL in the com-
plex with βCD and RAMEB was calculated to be  
88.87 % and 99.79 %, respectively. This confirmed the 
phase solubility data, which indicated RAMEB as a 
better complexing and solubilizing agent for ZAL com-
pared to the parent βCD. 
Two-dimensional rotating-frame Overhauser ef-
fect spectroscopy (ROESY) is a powerful technique for 
investigation of the inter- and intra-molecular interac-
tions. The presence of NOE cross-peak between the 
protons of two different species in a 2D ROESY spec-
trum is an indication that they are in a spatial contact 
within 3−5 Å.38 Therefore, to further confirm the actual 
inclusion complex formation and to give more insight 
into the binding mode of ZAL and the selected cyclo-
dextrins, 2D ROESY experiments were performed. In 
the 2D ROESY spectrum of ZAL/βCD complex, two 
groups of intermolecular NOE cross-peaks were ob-
served. The first group belongs to the interaction of the 
Ha and Hc protons of ZAL with the βCD protons (Fig-
ure 5A), while the second group corresponds to the 
interaction of the aromatic ZAL protons (Hd-HHj) and 
the βCD protons (Figure 5B). 
Both methyl protons (Ha and Hc) of the N-
ethylacetamide group of ZAL showed strong NOE 
cross-peaks with the H3, H6 and H5 protons of the 
βCD, confirming that they are included deeply into the 
cyclodextrin central cavity. The free rotation of N-
ethylacetamide group might allow its simultaneous 
interaction with both internal protons of the βCD. At 
the same time, NOE cross-peaks of the Ha and Hc 
protons of ZAL with the external βCD protons were 
also observed, but their intensity was significantly 
lower compared to those of the internal protons (Fig-
ure 5A), indicating that the inclusion of the N-
ethylacetamide into the central cavity was the domi-
nant binding mode. Interestingly, all aromatic protons 
showed NOE cross-peaks which indicated their inte-
ractions with both the internal (H3 and H5) but also 
the H6 protons, except in the case of Hi and Hd pro-
tons. Those protons did not show any NOE cross-
peaks corresponding to the interaction with the H3 
proton of the βCD (Figure 5B). Such results may lead 
to the conclusion that in the case of ZAL/βCD com-
plex, two binding modes exist simultaneously in the 
solution: the one in which the binding occurs by the 
inclusion of the phenyl ring of ZAL into the βCD cen-
tral cavity via the wider rim of the cyclodextrin cone 
(A) and the other by the inclusion of the pyrazolo[1,5-
a]pyrimidine ring (B), as suggested in Figure 6. This 
structure would allow the interaction of the methyl 
protons of the N-ethylacetamide group of ZAL with 
the external protons of the adjacent βCD molecule, 
resulting in weak NOE cross-peaks which may be 
observed in Figure 5A. But taking into account the 
stronger shielding effect for the Hd-Hf protons ob-
served by the one-dimensional 1H-NMR spectroscopy 
(Table 2), it might be concluded that the type A of 
inclusion (Figure 6A) is probably the dominant bind-
ing mode. The inclusion of one ZAL into two βCD 
molecules can be excluded, because phase solubility 
studies and spectrofluorimetry did not give any indica-
tion of a higher-order complex formation. Further-
more, the formation of higher order complexes is not 
very likely for drugs whose geometry is similar to 
ZAL due to sterical reasons, as discussed recently by 
Messner et al.39 
ROESY spectra of ZAL/RAMEB complex also 
showed two sets of NOE cross-peaks: the one belonging 
to the interaction of the Ha and Hc protons of ZAL with 
the RAMEB protons (Figure 5C) and the other belong-
ing to the interaction of the aromatic protons (Hd-Hj) of 
ZAL with the protons of the cyclodextrin derivative 
(Figure 5D). All signals were very intense and their 
overlapping was observed. Although these results un-
questionably confirmed the inclusion complex forma-
tion between ZAL and RAMEB, the elucidation of its 
structure might be rather ambiguous. However, the 
same binding mode as in the case of βCD can probably 
be assumed. The strong NOE cross-peaks between all 
the drug protons and the Me2 and Me6 of RAMEB 
confirmed their strong interaction with the drug mole-
cule upon the inclusion complex formation. 
Figure 6. The proposed structures of ZAL/βCD inclusion com-
plex deduced on the basis of 1H-NMR spectroscopy results. 
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CONCLUSION 
The results of the spectrofluorimetric and phase solu-
bility studies showed that the parent βCD and RAMEB 
are the most appropriate complexing agents for ZAL 
among the different studied cyclodextrin derivatives. 
The inclusion complex formation caused an enhanced 
florescence quantum yield and significantly improved 
the aqueous solubility of the drug. One- and two-
dimensional 1H-NMR studies confirmed the actual in-
clusion complex formation and gave some insight into 
the drug/cyclodextrin binding mode. Based on ROESY 
spectra, it was concluded that two binding modes of the 
ZAL/βCD complex exist simultaneously in the solution. 
The first one occurs by the inclusion of the phenyl ring 
of ZAL into the βCD central cavity via the wider rim of 
the cyclodextrin cone and the second occurs by the 
inclusion of the pyrazolo[1,5-a] pyrimidine ring of 
ZAL. The first one seems to be the dominant ZAL/βCD 
binding mode. 
Supplementary Materials. – Supporting informations to the 
paper are enclosed to the electronic version of the article. 
These data can be found on the website of Croatica Chemica 
Acta (http://public.carnet.hr/ccacaa). 
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